VEGFA and neoplasm: However, rapamycin, a compound used during the immunosuppressive Edmonton protocol [2], inhibits islet VEGF production and VEGF-mediated survival signalling in tumour cell lines [12]; this could have a major adverse effect on islet revascularisation and may contribute to graft failure over the longer term [13].